Celcuity Inc. (CELC): who owns it and who trades it
As of Nov 16, 2026, CELC insiders reported 17 open-market sales worth $328M and no purchases in the last 12 months, with 3% of the sale value made under pre-set 10b5-1 plans. The largest seller was Julian Baker (Other), with $318M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Celcuity
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CELC
274 funds and institutions reported CELC shares worth $6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 16.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7.92M | 16.38% | $828M | No change |
| Avoro Capital Advisors LLC | 3.40M | 7.03% | $356M | +1% |
| Rtw Investments, LP | 3.30M | 6.84% | $346M | +9% |
| Perceptive Advisors LLC | 3.20M | 6.61% | $334M | +2% |
| BlackRock, Inc. | 3.02M | 6.25% | $316M | +11% |
| State Street Corp | 1.96M | 4.05% | $205M | +29% |
| Vanguard Capital Management LLC | 1.87M | 3.88% | $196M | +5% |
| NEA Management Company, LLC | 1.71M | 3.54% | $179M | -25% |
| Soleus Capital Management, L.P. | 1.70M | 3.53% | $178M | +33% |
| Bank of America Corp | 1.47M | 3.04% | $154M | +106% |
| Deerfield Management Company, L.P. | 1.45M | 3.00% | $152M | -15% |
| Morgan Stanley | 1.33M | 2.76% | $140M | -1% |
| Tang Capital Management LLC | 1.31M | 2.72% | $138M | +25% |
| Toronto Dominion Bank | 1.26M | 2.60% | $132M | +43% |
| Geode Capital Management, LLC | 1.11M | 2.30% | $116M | +25% |
| T. Rowe Price Associates | 1.03M | 2.12% | $107M | -20% |
| Wellington Management Group LLP | 906,595 | 1.88% | $94.8M | +111% |
| Goldman Sachs Group Inc | 870,449 | 1.80% | $91.1M | +14% |
| Point72 Asset Management, L.P. | 650,916 | 1.35% | $68.1M | +132% |
| Hood River Capital Management LLC | 628,411 | 1.30% | $65.7M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CELC insiders reported $0 of open-market purchases and $328M of sales. 3% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Julian Baker +3 | Other | Sale | 2.84M | $102.50 | $291M | Form 4 |
| Jul 14, 2026 | Julian Baker +3 | Other | Sale | 261,368 | $102.50 | $26.8M | Form 4 |
| May 4, 2026 | David Dalvey | Director | Sale plan | 25,000 | $140.68 | $3.5M | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 2,825 | $142.04 | $401K | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 2,301 | $141.03 | $325K | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 1,670 | $139.58 | $233K | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 550 | $139.00 | $76.5K | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 1,289 | $137.00 | $177K | Form 4 |
| May 4, 2026 | Richard E Buller | Director | Sale plan | 365 | $143.24 | $52.3K | Form 4 |
| Mar 31, 2026 | Richard E Buller | Director | Sale plan | 2,325 | $110.11 | $256K | Form 4 |
| Mar 31, 2026 | Richard E Buller | Director | Sale plan | 675 | $110.83 | $74.8K | Form 4 |
| Jan 27, 2026 | David Dalvey | Director | Sale plan | 20,000 | $120.03 | $2.4M | Form 4 |
| Dec 5, 2025 | Richard E Buller | Director | Sale | 1,490 | $105.34 | $157K | Form 4 |
| Dec 5, 2025 | Richard E Buller | Director | Sale | 1,510 | $106.04 | $160K | Form 4 |
| Dec 1, 2025 | Richard E Buller | Director | Sale | 1,100 | $98.13 | $108K | Form 4 |
| Nov 21, 2025 | David Dalvey | Director | Sale plan | 15,000 | $100.00 | $1.5M | Form 4 |
| Nov 20, 2025 | Richard E Buller | Director | Sale | 3,900 | $96.73 | $377K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Julian Baker | Other | – | $318M | Jul 14, 2026 |
| David Dalvey | Director | – | $7.4M | May 4, 2026 |
| Richard E Buller | Director | – | $2.4M | May 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CELC short interest
Very high short interest. 21.0% of CELC shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 8%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.30M CELC shares were sold short, 21.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 1.76M shares, buying them all back would take about 5.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.30M | 20.97% | +0% | 1.76M | 5.8 |
| Oct 15, 2026 | 10.25M | 20.95% | -7% | 1.78M | 5.8 |
| Sep 30, 2026 | 10.98M | 22.44% | -3% | 995,703 | 11.0 |
| Sep 15, 2026 | 11.36M | 23.22% | +6% | 910,327 | 12.5 |
| Aug 31, 2026 | 10.69M | 21.84% | +1% | 679,969 | 15.7 |
| Aug 14, 2026 | 10.54M | 21.53% | +3% | 796,592 | 13.2 |
| Jul 31, 2026 | 10.26M | 21.23% | -8% | 1.52M | 6.8 |
| Jul 15, 2026 | 11.15M | 23.07% | +2% | 1.97M | 5.7 |
| Jun 30, 2026 | 10.97M | 22.69% | +3% | 1.28M | 8.6 |
| Jun 15, 2026 | 10.67M | 22.07% | +11% | 2.45M | 4.3 |
| May 29, 2026 | 9.60M | 19.86% | +0% | 795,120 | 12.1 |
| May 15, 2026 | 9.56M | 19.77% | +7% | 1.60M | 6.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Celcuity company events
Celcuity filed 16 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 2, 2026LeadershipThe Board of Directors of Celcuity Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from eight members to nine members and to appoint David W. Gryska as a new director to fill the resulting vacancy, effective… Filing
- Sep 30, 2026AnnouncementThe Company issued a press release announcing that REVTORPYK is now commercially available in the United States for eligible patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic… Filing
- Aug 26, 2026AnnouncementThe Company issued a press release announcing the submission of its sNDA to the FDA for REVTORPYK for the treatment of patients with HR+/HER2- ABC with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 15, 2026AnnouncementAmended an earlier report. The Company issued a press release announcing FDA approval of REVTORPYK for the treatment of patients with HR+/HER2-, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the… Filing
- Jul 15, 2026AnnouncementThe Company issued a press release announcing FDA approval of REVTORPYK for the treatment of patients with HR+/HER2-, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the… Filing
- Jun 8, 2026AgreementCelcuity Inc. entered into an underwriting agreement with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, agreeing, subject to customary conditions, to issue and sell in a public… Filing
- Jun 2, 2026AnnouncementThe Company announced detailed efficacy and safety results from the PIK3CA MT cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive, human epidermal growth factor receptor 2 negative, PIK3CA MT… Filing
- May 20, 2026LeadershipAmended an earlier report. The Board of Directors of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy… Filing
- May 18, 2026LeadershipCelcuity Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 14, 2026ResultsReleased financial results. Filing
- May 1, 2026AnnouncementThe Company issued a press release announcing positive topline results from the PIK3CA mutant cohort of the VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- ABC, following progression on or after treatment with a CDK4/6 inhibitor and… Filing
- Mar 25, 2026ResultsReleased financial results. Filing
- Feb 12, 2026LeadershipThe Board of Directors of Celcuity Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy… Filing
- Nov 17, 2025AnnouncementThe Company issued a press release announcing the submission of its NDA to the FDA for gedatolisib in HR+/HER2- PIK3CA wild-type ABC. Item 9.01 Financial Statements and Exhibits. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Celcuity financials
Famous investors that hold CELC
4 of the 50 well-known investors we track reported holding CELC in their latest 13F filing. The largest position is Steve Cohen's, worth $140M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.76M | $140M | 0.2% | +171% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 600,374 | $47.7M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 66,701 | $5.3M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 24,094 | $1.9M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CELC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G/A | 3.1% |
| Nov 16, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 3.7% |
| Nov 16, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 3.7% |
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G/A | 3.1% |
Questions about Celcuity Inc. (CELC) stock
Who owns the most CELC stock?
The largest reported owner of Celcuity Inc. (CELC) is Baker Bros. Advisors LP, with 16.4% of the company. In total, 274 funds and institutions reported holding CELC at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CELC insiders buying or selling?
In the last 12 months, CELC insiders reported no open-market purchases and 17 sales worth $328M. The latest trade was on Jul 14, 2026. See every trade.
What is the short interest in CELC?
As of Oct 30, 2026, 10.30M CELC shares were sold short, 21.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 1.76M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.
Which famous investors hold CELC?
4 of the 50 well-known investors we track reported CELC in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $140M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.